Discontinued — last reported Q4 '24
Business Segments · Acquisitions
Emerging Markets — Acquisitions
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ1 2019
Last reportedQ4 2024Feb 26, 2026
Rolls up toGoodwill Additions
How to read this metric
An increase suggests an aggressive inorganic growth strategy in developing regions, while zero values indicate a focus on organic growth or capital preservation.
Detailed definition
Represents the total capital expenditure or investment value allocated to acquiring new businesses or product lines spec...
Peer comparison
Commonly reported by multinational pharmaceutical companies as 'M&A activity' or 'Business acquisitions' within regional segment disclosures.
Metric ID:
vtrs_segment_emerging_markets_acquisitionsHistorical Data
8 periods
| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | |
|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Range$0.00 – $0.00
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Viatris's emerging markets — acquisitions?
- Viatris (VTRS) reported emerging markets — acquisitions of $0.00 in Q4 2024.
- What does emerging markets — acquisitions mean?
- The total cost of business acquisitions made within the Emerging Markets segment.